NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that a Phase II clinical trial of its anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody IMC-A12 in patients with head and neck cancer has commenced patient enrollment.
